Page last updated: 2024-11-03

primaquine and Latent Infection

primaquine has been researched along with Latent Infection in 1 studies

Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.

Latent Infection: Delayed infection of the host by a dormant or inactive pathogen.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Satyagraha, AW1
Sadhewa, A1
Panggalo, LV1
Subekti, D1
Elyazar, I1
Soebianto, S1
Mahpud, N1
Harahap, AR1
Baird, JK1

Other Studies

1 other study available for primaquine and Latent Infection

ArticleYear
Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria.
    PLoS neglected tropical diseases, 2021, Volume: 15, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Female; Gene Expression Regulation

2021